Does dulaglutide reduce heart attack risk?

Yes, its own randomized trial demonstrated a cardiovascular risk reduction, which is part of why it carries that indication on its FDA approved label as Trulicity. This is a separate, drug specific trial result, not something that automatically applies to every drug in the GLP-1 class just because they share a receptor target.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.